Revelation Biosciences, Inc. (NASDAQ:REVB – Get Free Report) was the target of a large increase in short interest in the month of October. As of October 30th, there was short interest totaling 12,792 shares, an increase of 93.7% from the October 15th total of 6,605 shares. Currently, 2.0% of the company’s stock are sold short. Based on an average daily trading volume, of 39,572 shares, the days-to-cover ratio is currently 0.3 days.
Revelation Biosciences Price Performance
Shares of Revelation Biosciences stock opened at $3.73 on Tuesday. The business’s fifty day moving average price is $5.09 and its two-hundred day moving average price is $7.36. The company has a market capitalization of $2.53 million, a P/E ratio of -0.09 and a beta of -0.13. Revelation Biosciences has a 1-year low of $3.08 and a 1-year high of $40.60.
Revelation Biosciences (NASDAQ:REVB – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($5.92) EPS for the quarter, beating analysts’ consensus estimates of ($6.16) by $0.24. On average, research analysts expect that Revelation Biosciences will post -24.53 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Separately, Weiss Ratings raised shares of Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, November 10th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Revelation Biosciences currently has a consensus rating of “Sell”.
Read Our Latest Stock Analysis on Revelation Biosciences
About Revelation Biosciences
Revelation Biosciences is a clinical-stage biotechnology company developing treatments that target the innate immune system. Its research focuses on potential therapies for infectious and other diseases. The company’s lead program, Gemini, is an intranasal formulation of an immune-stimulating compound designed to activate Toll-like receptor 4. Revelation has investigated Gemini as a potential way to help prevent or treat respiratory infections. Revelation’s work is centered on developing its therapeutic candidates; the company has not established a broad commercial product portfolio.
Further Reading
- Five stocks we like better than Revelation Biosciences
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
